Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | APN401 |
Synonyms | |
Therapy Description |
APN401 is composed of autologous peripheral blood mononuclear cells in which Cbl-b has been silenced with siRNA, which potentially results in increased anti-tumor immune response upon infusion (J Clin Oncol 34, 2016 (suppl; abstr e14541)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APN401 | APN401 is composed of autologous peripheral blood mononuclear cells in which Cbl-b has been silenced with siRNA, which potentially results in increased anti-tumor immune response upon infusion (J Clin Oncol 34, 2016 (suppl; abstr e14541)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03087591 | Phase I | APN401 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT06172894 | Phase I | APN401 | PBMC-based Leukocyte Immunotherapy (PALINDROM) | Recruiting | AUT | 0 |